Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88782 | 0.83 | CA9 (0.41) | CA1CA2CA9MEN1NPC1 | |
| SCHEMBL31003510 | 0.69 | CA9 (0.46) | CA1CA2CA9MEN1NPC1 | |
| SCHEMBL62430 | 0.69 | CA9 (0.46) | CA1CA2CA9MEN1NPC1 | |
| SCHEMBL7133253 | 0.68 | CYP1A2 (0.46) | CA1CA2CA9MEN1NPC1 | |
| SCHEMBL7560150 | 0.67 | — | — | |
| SCHEMBL17292531 | 0.66 | DAO (0.31) | — | |
| SCHEMBL17292502 | 0.66 | CSNK1D (0.31) | CA9CA12 | |
| SCHEMBL25351599 | 0.64 | CA1 (0.39) | CA1CA2CA9MEN1NPC1 | |
| SCHEMBL21157146 | 0.64 | GPR3 (0.44) | MEN1KMT2A | |
| SCHEMBL30648691 | 0.63 | SIGMAR1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4540230-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244710-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023138589-A1 | FIVE-MEMBERED HETEROCYCLIC PYRIMIDINE DERIVATIVE AND USE THEREOF AS INHIBITOR OF PAN-KRAS MUTATION | 思路迪生物医药(上海)有限公司 | 2023-07-27 | — | — | WO | disclosed |
| EP-3489233-B1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3489233-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8163773-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | NOVARTIS AG (CH) | 2010-06-24 | — | — | US | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090281161-A1 | Organic Compounds | MAIBAUM JUERGEN KLAUS | 2009-11-12 | — | — | US | disclosed |
| US-20090270417-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-29 | — | — | US | disclosed |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | CA1 1431/4885CA2 2940/4885CA9 2619/4885 |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | CA1 2395/4885CA2 1331/4885CA9 1069/4885 |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | CA1 2086/4885CA2 905/4885CA9 1046/4885 |
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | CA1 2109/4885CA2 568/4885CA9 639/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | CA1 2037/4885CA2 562/4885CA9 630/4885 |
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | NR3C2, CRHR2, TPH2 | CA1 2773/4885CA2 1032/4885CA9 2710/4885 |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | NR3C2, CRHR2, TPH2 | CA1 2773/4885CA2 1032/4885CA9 2710/4885 |
| US-20090281161-A1 | Organic Compounds | REN, ACE, OTC | CA1 1342/4885CA2 524/4885CA9 265/4885 |
| US-20090270417-A1 | Organic Compounds | REN, ACE, OTC | CA1 1342/4885CA2 524/4885CA9 265/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | CA1 1761/4885CA2 494/4885CA9 611/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | CA1 1646/4885CA2 418/4885CA9 501/4885 |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | REN, ACE, PIGO | CA1 2637/4885CA2 1064/4885CA9 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.